The status of Msh2 in tumors is often assessed using immunohistochemistry (IHC) to detect the presence or absence of the Msh2 protein in tissue samples. Loss of Msh2 expression suggests MMR deficiency. Additionally, genetic testing may be employed to identify specific mutations in the Msh2 gene, particularly in patients suspected of having Lynch syndrome.
